ClinicalTrials.gg
TerminatedNCT01633112ASSESSUpdated May 28, 2019Results posted

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

A Phase 3 interventional study of fingolimod and glatiramer acetate in Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Novartis Pharmaceuticals. Terminated at 130 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,064
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
3rd of 19
1,064 · median 142
Started
2012
with 3 others
Phase 3
5 of 19
none open now
Registered
12th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 12th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS

Read the detailed description

This was a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatimer acetate 20 mg s.c. in patients with RRMS.

This study consisted of 3 periods:

  • Screening Period: up to 45 days for all patients
  • Treatment Period: 12 months of glatiramer acetate 20 mg, fingolimod 0.25 mg, or fingolimod 0.5 mg
  • Follow-up occurred 3 months (12 weeks) after the last dose of study drug for all patients The informed consent form was signed prior to any study related activities at the screening visit. Randomization to either treatment group was preformed at visit 1 after a diligent check of applicable in- and exclusion criteria in a 1:1:1 ratio (changed to 5:3:2 after implementation of Amendment 2 in 2015).

Treatment groups:

  • fingolimod 0.5 mg/day orally for up to 12 months
  • fingolimod 0.25 mg/day orally for up to 12 months
  • glatiramer acetate 20 mg/day subcutaneously for up to 12 months
03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis (RRMS)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Male and female patients 18 to 65 years of age, inclusive.
  • Patients with RRMS, as defined by 2010 revised McDonald criteria.
  • Patients must be neurologically stable with no onset of relapse within 30 days of randomization
  • Patients with at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years before randomization.
  • Patients with an EDSS score of 0 to 6, inclusive, at Screening. A score of 6.0 indicates unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting.

Exclusion criteria

Exclusion criteria:

  • Patients with a history of of any organ system (other than cutaneous basal cell carcinoma) in the last 5 years that do not have confirmation of absence of a malignancy prior to randomization
  • Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjogren's syndrome, Crohn's disease, ulcerative colitis) or with a known immunodeficiency syndrome (-antibody positive, AIDS, hereditary immune deficiency, drug-induced immune deficiency).
  • Patients who have been treated with:
  • High-dose intravenous (IV) immunoglobulin (Ig) within 4 weeks before randomization
  • /chemotherapeutic medications (e.g., azathioprine, cyclophosphamide, methotrexate) within 6 months before randomization
  • Natalizumab within 2 months before randomization
  • Previous treatment with lymphocyte-depleting therapies (e.g., rituximab, alemtuzumab, ofatumumab, ocrelizumab, or cladribine) within 1 year before randomization Previous treatment with mitoxantrone within 6 months before randomization
  • Use of teriflunomide within 3.5 months prior to randomization, except if active washout (with either cholestyramine or activated charcoal) was done. In that case, plasma levels are required to be measured and be below 0.02 mg/L before randomization.

No is necessary for patients treated with dimethyl fumarate, interferon (IFN) beta, or glatiramer acetate.

Patients being treated with dimethyl fumarate, glatiramer acetate, or IFN beta at the Screening visit can continue drug intake up to the day before Day 1 of this study (i.e., there is no need for a washout period).

  • Patients who have been treated with systemic or adrenocorticotropic hormones in the past 30 days prior to the screening magnetic resonance imaging (MRI) procedure.
  • Patients with uncontrolled diabetes mellitus (glycosylated >9%) or with diabetic neuropathy.
  • Patients with a diagnosis of macular edema during Screening (patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at Screening).
  • Patients with severe active bacterial, viral, or fungal infections.
  • Patients without acceptable evidence of immunity to varicella zoster virus (VZV) at randomization.
  • Patients who have received any live or (including VZV, herpes simplex, or measles) within 1 month before randomization.
  • Patients who have received total lymphoid irradiation or bone marrow transplantation.
  • Patients with any unstable medical/psychiatric condition, as assessed by the primary treating physician at each site.
  • Patients who in the last 6 months experienced any of the following cardiovascular conditions or findings in the screening (ECG): myocardial infarction, unstable angina, stroke, or decompensated heart failure requiring hospitalization or Class III/IV heart failure.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,064 participants (actual)

Study arms

  • Experimental
    fingolimod 0.5 mg

    orally once daily

    Drug: fingolimod

  • Experimental
    fingolimod 0.25mg

    orally once daily

    Drug: fingolimod

  • Active comparator
    glatiramer acetate 20 mg

    subcutaneous once daily

    Drug: glatiramer acetate

Interventions

  • capsule

    Also known as: FTY720, fingolimod hydrochloride,, Gilenya

  • subcutaneous injection

    Also known as: Copaxone, Glatopa

06

What researchers measure

Primary outcomes

  1. Confirmed Annualized Relapse Rate

    Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study.

    Time frame: up to 12 months

Secondary outcomes

  1. New or Newly Enlarging T2 Lesions

    Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.

    Time frame: At 12 months/end of study

  2. Number of Participants Free of New/Newly Enlarged T2 Lesions

    Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.

    Time frame: At 12 months/end of study

  3. Change From Baseline in T2 Lesion Volume

    Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume

    Time frame: Baseline, 12 months/end of study

  4. Gd Enhancing T1 Lesion Count

    Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count

    Time frame: At 12 months/end of study

  5. Gd Enhancing T1 Lesion Volume

    Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count

    Time frame: Baseline, 12 months/end of study

  6. Percentage of Patients Free of New T1 Hypointense Lesions

    Based on MRI measures of new T1 hypointense lesions

    Time frame: 12 months

  7. Change From Baseline in TSQM Scales

    Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.

    Time frame: 6 months, 12 months/end of study

  8. Percent Brain Volume Change From Baseline

    Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation.

    Time frame: Baseline, 12 months, end of study

07

Results

Posted May 28, 2019
Limitations and caveats
Terminated due to slow recruitment.

Participant flow

Participant flow — Overall Study
MilestoneFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Started352370342
Completed299310250
Not completed536092
Withdrew: Lack of efficacy1613
Withdrew: Abnormal laboratory value(s)310
Withdrew: Abnormal test procedure result(s)010
Withdrew: Administrative problems125
Withdrew: Adverse event161820
Withdrew: Lost to follow-up7196
Withdrew: Protocol violation402
Withdrew: Subject no longer requires study drug001
Withdrew: Withdrawal by subject201241
Withdrew: Missing study completion crf114

Outcome measures

PrimaryConfirmed Annualized Relapse Rate

Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study.

Time frame:
up to 12 months
Reported as:
Number · relapses/year
Confirmed Annualized Relapse Rate
relapses/yearFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Confirmed Annualized Relapse Rate0.153 (0.111 to 0.212)0.221 (0.168 to 0.290)0.258 (0.196 to 0.341)
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · negative binomial regression model · p = 0.0138adjusted for treatment, geographical region, number of relapses in the previous year, baseline EDSS, and baseline Gd-enhancing T1 lesion count.
  • FTY720 0.25 mg vs GA 20 mg · negative binomial regression model · p = 0.4153adjusted for treatment, geographical region, number of relapses in the previous year, baseline EDSS, and baseline Gd-enhancing T1 lesion count.
SecondaryNew or Newly Enlarging T2 Lesions

Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.

Time frame:
At 12 months/end of study
Reported as:
Mean · Lesions
New or Newly Enlarging T2 Lesions
LesionsFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
New or Newly Enlarging T2 Lesions2.6 ± 5.423.3 ± 6.945.7 ± 10.71
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · negative binomial regression model · p = <0.0001Adjusted for treatment, geog. region, age, baseline T2 lesion count, baseline Gd-enhancing T1 lesion count, and the number of previous year relapses.
  • FTY720 0.25 mg vs GA 20 mg · negative binomial regression model · p = <0.0001Adjusted for treatment, geog. region, age, baseline T2 lesion count, baseline Gd-enhancing T1 lesion count, and the number of previous year relapses.
SecondaryNumber of Participants Free of New/Newly Enlarged T2 Lesions

Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.

Time frame:
At 12 months/end of study
Reported as:
Number · Participants
Number of Participants Free of New/Newly Enlarged T2 Lesions
ParticipantsFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Number of Participants Free of New/Newly Enlarged T2 Lesions15615596
SecondaryChange From Baseline in T2 Lesion Volume

Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume

Time frame:
Baseline, 12 months/end of study
Reported as:
Mean · cubic centimeters (cc)
Change From Baseline in T2 Lesion Volume
cubic centimeters (cc)FTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Change From Baseline in T2 Lesion Volume-0.14 ± 1.583-0.05 ± 2.3400.42 ± 2.305
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · ANCOVA · p = <0.0001rank ANCOVA with covariates: adjusted for treatment, age, region, number of relapses experienced in the previous year, and baseline T2 lesion volume.
  • FTY720 0.25 mg vs GA 20 mg · ANCOVA · p = 0.0060rank ANCOVA with covariates: adjusted for treatment, age, region, number of relapses experienced in the previous year, and baseline T2 lesion volume.
SecondaryGd Enhancing T1 Lesion Count

Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count

Time frame:
At 12 months/end of study
Reported as:
Mean · lesions
Gd Enhancing T1 Lesion Count
lesionsFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Gd Enhancing T1 Lesion Count0.4 ± 1.570.4 ± 1.560.9 ± 3.67
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · negative binomial regression model · p = 0.0167adjusted for treatment, age, geog. region, baseline T2 lesion count, baseline Gd-enhancing T1 lesion count, and the number of previous year relapses .
  • FTY720 0.25 mg vs GA 20 mg · negative binomial regression model · p = 0.0011adjusted for treatment, age, geog. region, baseline T2 lesion count, baseline Gd-enhancing T1 lesion count, and the number of previous year relapses.
SecondaryGd Enhancing T1 Lesion Volume

Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count

Time frame:
Baseline, 12 months/end of study
Reported as:
Mean · cubic centimeter
Gd Enhancing T1 Lesion Volume
cubic centimeterFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Baseline0.31 ± 1.0670.32 ± 1.4210.22 ± 0.841
Month 12/end of study0.06 ± 0.2150.05 ± 0.1810.12 ± 0.450
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · ANCOVA · p = 0.0052ranked ANCOVA with covariates: treatment, region, age, baseline Gd-enhancing T1 lesion volume, and number ofrelapses experienced in the previous year.
  • FTY720 0.25 mg vs GA 20 mg · ANCOVA · p = 0.0636ranked ANCOVA with covariates: treatment, region, age, baseline Gd-enhancing T1 lesion volume, and number ofrelapses experienced in the previous year.
SecondaryPercentage of Patients Free of New T1 Hypointense Lesions

Based on MRI measures of new T1 hypointense lesions

Time frame:
12 months
Reported as:
Number · Percentage
Percentage of Patients Free of New T1 Hypointense Lesions
PercentageFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Percentage of Patients Free of New T1 Hypointense Lesions55.352.144.3
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · Regression, Logistic · p = 0.0011 (adjusted for treatment, region, age, proper baseline T1 lesion variable, baseline Gd-enhancing T1 lesion count and number of previous year relapses.)pair-wise comparisons between treatment groups using a logistic regression model.
  • FTY720 0.25 mg vs GA 20 mg · Regression, Logistic · p = 0.0146 (adjusted for treatment, region, age, proper baseline T1 lesion variable, baseline Gd-enhancing T1 lesion count and number of previous year relapses.)pair-wise comparisons between treatment groups using a logistic regression model.
SecondaryChange From Baseline in TSQM Scales

Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.

Time frame:
6 months, 12 months/end of study
Reported as:
Mean · score on a scale
Change From Baseline in TSQM Scales
score on a scaleFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Global Satisfaction (Month 6)20.8 ± 28.1523.4 ± 27.0414.4 ± 25.42
Global Satisfaction (Month 12)19.2 ± 31.8720.5 ± 32.219.4 ± 30.43
Effectiveness (Month 6)15.2 ± 25.9618.2 ± 25.0512.9 ± 23.43
Effectiveness (Month 12)16.8 ± 26.8517.9 ± 28.298.0 ± 27.38
Side Effects (Month 6)16.9 ± 31.5818.8 ± 30.639.3 ± 31.94
Side Effects (Month 12)16.2 ± 31.5217.2 ± 32.527.6 ± 32.76
Convenience (Month 6)30.7 ± 25.7626.5 ± 25.934.4 ± 20.73
Convenience (Month 12)29.5 ± 24.4226.5 ± 26.360.8 ± 25.72
Statistical analysis
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 6): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 12): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = <0.0001Global Satisfaction (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 6): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 12): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = <0.0001Effectiveness (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Side Effects (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Side Effects (Month 6): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = 0.0005Side Effects (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0051Side Effects (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Side Effects (Month 12): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = 0.0051Side Effects (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Convenience (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Convenience (Month 6): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = 0.0068Convenience (Month 6): p-values for within treatment comparison from baseline
  • FTY720 0.5 mg · Wilcoxon signed-rank test · p = <0.0001Convenience (Month 12): p-values for within treatment comparison from baseline
  • FTY720 0.25 mg · Wilcoxon signed-rank test · p = <0.0001Convenience (Month 12): p-values for within treatment comparison from baseline
  • GA 20 mg · Wilcoxon signed-rank test · p = 0.4595Convenience (Month 12): p-values for within treatment comparison from baseline
SecondaryPercent Brain Volume Change From Baseline

Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation.

Time frame:
Baseline, 12 months, end of study
Reported as:
Mean · Percentages of volume change
Percent Brain Volume Change From Baseline
Percentages of volume changeFTY720 0.5 mgFTY720 0.25 mgGA 20 mg
Percent Brain Volume Change From Baseline-0.652 ± 0.7810-0.636 ± 0.8097-0.561 ± 0.7819
Statistical analysis
  • FTY720 0.5 mg vs GA 20 mg · ANCOVA · p = 0.1045rank ANCOVA model adjusted for treatment, region, age, the number of relapses experienced in the previous year, and baseline normalized brain volume
  • FTY720 0.25 mg vs GA 20 mg · ANCOVA · p = 0.1358rank ANCOVA model adjusted for treatment, region, age, the number of relapses experienced in the previous year, and baseline normalized brain volume

Adverse events

Collected over Adverse Events (AEs) and Serious AEs (SAEs) were collected during treatment exposure and follow up where: AE summaries on the follow-up set were conducted for time periods defined by days relative to study drug discontinuation: days 1 - 45 after discontinuation, or day 46 or later after drug discontinuation. For SAEs (death and non-fatal ), all SAEs starting after the first dose date, including those starting > 45 days after study drug discontinuation, were included in the safety set summaries.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5 mg0/345 (0%)25/345 (7.2%)214/345 (62%)
FTY 0.25 mg0/366 (0%)32/366 (8.7%)245/366 (66.9%)
GA 20 mg0/324 (0%)20/324 (6.2%)190/324 (58.6%)
All@Patients0/1,035 (0%)77/1,035 (7.4%)649/1,035 (62.7%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventFingolimod 0.5 mgFTY 0.25 mgGA 20 mgAll@Patients
Multiple sclerosis relapseNervous system disorders4/3457/3667/32418/1035
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3454/3660/3247/1035
HeadacheNervous system disorders1/3453/3660/3244/1035
Urinary tract infectionInfections and infestations2/3451/3662/3245/1035
SyncopeNervous system disorders0/3450/3662/3242/1035
DyspnoeaRespiratory, thoracic and mediastinal disorders2/3450/3660/3242/1035
LeukocytosisBlood and lymphatic system disorders0/3452/3660/3242/1035
Gait disturbanceGeneral disorders0/3452/3660/3242/1035
SeizureNervous system disorders1/3452/3660/3243/1035
Acute myocardial infarctionCardiac disorders0/3450/3661/3241/1035
Most frequent other events
Showing 10 of 21
Most frequent other events
EventFingolimod 0.5 mgFTY 0.25 mgGA 20 mgAll@Patients
HeadacheNervous system disorders51/34550/36627/324128/1035
FatigueGeneral disorders46/34546/36622/324114/1035
Urinary tract infectionInfections and infestations44/34543/36635/324122/1035
Injection site painGeneral disorders0/3450/36636/32436/1035
Injection site erythemaGeneral disorders0/3450/36634/32434/1035
Upper respiratory tract infectionInfections and infestations30/34535/36620/32485/1035
HypertensionVascular disorders26/34534/36612/32472/1035
NauseaGastrointestinal disorders24/34530/36615/32469/1035
Injection site pruritusGeneral disorders0/3450/36626/32426/1035
DizzinessNervous system disorders12/34527/36614/32453/1035

Baseline characteristics

Ramdomized set: All subjects who were assigned randomization numbers. The subjects in this set were called randomized subjects. This set was used to summarize subject disposition, demographic and baseline characteristics, and protocol deviation information. Subjects were grouped according to randomized treatment.

Age, Continuous
Age, Continuous(Years)FTY720 0.5 mgFTY720 0.25 mgGA 20 mgTotal
Mean40.3 ± 11.1238.9 ± 11.0139.6 ± 10.8039.6 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)FTY720 0.5 mgFTY720 0.25 mgGA 20 mgTotal
Female264276252792
Male889490272
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FTY720 0.5 mgFTY720 0.25 mgGA 20 mgTotal
Caucasian268279243790
Black344341118
Asian0101
Native American87924
Pacific Islander0101
Other423949130
08

Study locations

130 sites
  • Novartis Investigative Site
    Cullman, Alabama 35058, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85004, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85013, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85018, United States
  • Novartis Investigative Site
    Tucson, Arizona 85741, United States
  • Novartis Investigative Site
    Los Angeles, California 90089, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Boulder, Colorado 80304, United States
  • Novartis Investigative Site
    Denver, Colorado 80220, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80528, United States
  • Novartis Investigative Site
    Loveland, Colorado 80538, United States
  • Novartis Investigative Site
    Fairfield, Connecticut 06824, United States
  • Novartis Investigative Site
    Newark, Delaware 19713, United States
  • Novartis Investigative Site
    Washington, District of Columbia 20007, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32209, United States
  • Novartis Investigative Site
    Maitland, Florida 32751, United States
  • Novartis Investigative Site
    Naples, Florida 34119, United States
  • Novartis Investigative Site
    New Port Richey, Florida 34653, United States
  • Novartis Investigative Site
    Orlando, Florida 32806, United States
  • Novartis Investigative Site
    Ormond Beach, Florida 32174, United States
  • Novartis Investigative Site
    Pompano Beach, Florida 33060, United States
  • Novartis Investigative Site
    Ponte Vedra Beach, Florida 32082-4627, United States
  • Novartis Investigative Site
    Port Charlotte, Florida 33952, United States
  • Novartis Investigative Site
    Sarasota, Florida 34243, United States
  • Novartis Investigative Site
    Tallahassee, Florida 32308, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Vero Beach, Florida 32960, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33407, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30327, United States
  • Novartis Investigative Site
    Elk Grove Village, Illinois 60007, United States
  • Novartis Investigative Site
    Evanston, Illinois 60201, United States
  • Novartis Investigative Site
    Flossmoor, Illinois 60422, United States
  • Novartis Investigative Site
    Northbrook, Illinois 60062, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46202, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    West Des Moines, Iowa 50314, United States
  • Novartis Investigative Site
    Kansas City, Kansas 66160, United States
  • Novartis Investigative Site
    Lenexa, Kansas 66212, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40207, United States
  • Novartis Investigative Site
    Hammond, Louisiana 70403, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70121, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02215, United States
  • Novartis Investigative Site
    Springfield, Massachusetts 01104, United States
  • Novartis Investigative Site
    Detroit, Michigan 48201, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Farmington Hills, Michigan 48334, United States
  • Novartis Investigative Site
    Grand Rapids, Michigan 49503, United States
  • Novartis Investigative Site
    Traverse City, Michigan 49684-2340, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64111, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63104, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63131, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Great Falls, Montana 59405, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89106, United States
  • Novartis Investigative Site
    Freehold, New Jersey 07728, United States
  • Novartis Investigative Site
    Newark, New Jersey 07103, United States
  • Novartis Investigative Site
    Teaneck, New Jersey 07666, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87131, United States
  • Novartis Investigative Site
    Albany, New York 12208, United States
  • Novartis Investigative Site
    Amherst, New York 14226, United States
  • Novartis Investigative Site
    Buffalo, New York 14203, United States
  • Novartis Investigative Site
    Patchogue, New York 11772, United States
  • Novartis Investigative Site
    Rochester, New York 14642, United States
  • Novartis Investigative Site
    Stony Brook, New York 11794, United States
  • Novartis Investigative Site
    Syracuse, New York 13210, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27599-9500, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28204, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Novartis Investigative Site
    Akron, Ohio 44320, United States
  • Novartis Investigative Site
    Bellevue, Ohio 44811, United States
  • Novartis Investigative Site
    Columbus, Ohio 43210, United States
  • Novartis Investigative Site
    Columbus, Ohio 43221, United States
  • Novartis Investigative Site
    Dayton, Ohio 45408, United States
  • Novartis Investigative Site
    Toledo, Ohio 43614, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Tulsa, Oklahoma 74137, United States
  • Novartis Investigative Site
    Portland, Oregon 97225, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19141, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29302, United States
  • Novartis Investigative Site
    Cordova, Tennessee 38018, United States
  • Novartis Investigative Site
    Knoxville, Tennessee 37934, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37204, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37205, United States
  • Novartis Investigative Site
    Dallas, Texas 75214, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Round Rock, Texas 78681, United States
  • Novartis Investigative Site
    San Antonio, Texas 78258, United States
  • Novartis Investigative Site
    Sherman, Texas 75092, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84103, United States
  • Novartis Investigative Site
    Alexandria, Virginia 22310, United States
  • Novartis Investigative Site
    Charlottesville, Virginia 22903, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Richmond, Virginia 23226, United States
  • Novartis Investigative Site
    Roanoke, Virginia 24018, United States
  • Novartis Investigative Site
    Issaquah, Washington 98029, United States
  • Novartis Investigative Site
    Seattle, Washington 98101, United States
  • Novartis Investigative Site
    Seattle, Washington 98122-4379, United States

Showing the first 100 of 130 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2020 Aug 24;78(1):1-13. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print. PubMed 32852530 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2012 to primary completion in Apr 2018, 68 months.

Results were first posted in May 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2012
First posted
Jul 4, 2012
StartActual
Aug 9, 2012
Primary completionActual
Apr 30, 2018
CompletionActual
Apr 30, 2018
Results first posted
May 28, 2019
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01633112
Responsible party
Sponsor
First posted
Jul 4, 2012
Start date
Aug 9, 2012
Primary completion
Apr 30, 2018
Completion
Apr 30, 2018
Results posted
May 28, 2019
Last update
May 28, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion